Financial News

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Apellis Pharmaceuticals, Inc. - Common Stock (NQ: APLS )

28.25 +0.07 (+0.23%)
Streaming Delayed Price Updated: 3:06 PM EST, Feb 19, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Apellis Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
17 18 Next >
APELLIS ALERT: Bragar Eagel & Squire, P.C. is Investigating Apellis Pharmaceuticals, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
21 Analysts Have This to Say About Apellis Pharmaceuticals
Via Benzinga
Apellis Pharmaceuticals Reports Third Quarter 2023 Financial Results
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
Inside Cathie Wood’s Portfolio: 3 Stocks She Is Betting Millions On
Are you looking to invest in disrupting stocks like Cathie Woods? Here are three stocks Cathie Wood is betting millions on. 
Via InvestorPlace
Analyst Ratings for Apellis Pharmaceuticals
Via Benzinga
Why Apellis Pharmaceuticals Stock Popped Today
Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) shares are trading higher Thursday after the company reported preliminary U.S. 
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Apellis Pharmaceuticals Stock Improves With An RS Ratings Over 90
Apellis Pharmaceuticals shows improving price performance, earning an upgrade to its IBD Relative Strength Rating. 
Via Investor's Business Daily
Apellis Pharmaceuticals to Host Conference Call on November 1, 2023, to Discuss Third Quarter 2023 Financial Results
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
Apellis Pharmaceuticals Stock Shows Rising Relative Strength
A Relative Strength Rating upgrade for Apellis Pharmaceuticals shows improving technical performance. Will it continue? 
Via Investor's Business Daily
The Lancet Publishes 24-Month Results from Phase 3 Studies of SYFOVRE® (pegcetacoplan injection) for Geographic Atrophy (GA)
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Apellis to Present Positive Phase 2 NOBLE Results of Pegcetacoplan in Post-Transplant Recurrence of Primary IC-MPGN and C3G at Kidney Week
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
Stocks Mixed Amid Earnings, Consumer Sentiment Data
Stocks are mixed this afternoon, as investors unpack earnings reports from several bank giants as well as economic data. 
Via Talk Markets
JPMorgan, Wells Fargo, Citigroup And Other Big Stocks Moving Higher On Friday
U.S. stocks traded mostly higher, with the Dow Jones gaining more than 100 points on Friday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
Topics Stocks
Exposures US Equities
Why Pioneer Natural Resources Shares Are Bouncing By Around 12%; Here Are 20 Stocks Moving Premarket
Gainers Vaccinex, Inc. (NASDAQ: VCNX) shares rose 40.2% to $1.15 in pre-market trading as two large insider buys were reported after the close on Thursday. 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For October 6, 2023
Via Benzinga
Constellation Brands To Rally Over 20%? Here Are 10 Other Analyst Forecasts For Friday
HSBC raised the price target for Constellation Brands, Inc. (NYSE: STZ) from $280 to $290. HSBC analyst Carlos Laboy maintained a Buy rating. Constellation shares fell 3.2% to close at $241.33 on... 
Via Benzinga
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
Apellis Announces Preliminary U.S. Net Revenues of Approximately $74 Million for SYFOVRE® (pegcetacoplan injection) in the Third Quarter of 2023
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
APLS DEADLINE TODAY: ROSEN, A LEADING NATIONAL FIRM, Encourages Apellis Pharmaceuticals, Inc. Investors to Secure Counsel Before Important October 2 Deadline in Securities Class Action - APLS
WHY: NEW YORK, NY - (NewMediaWire) - October 2, 2023 - Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) between... 
Via TheNewswire.com
Topics Lawsuit
Exposures Financial Legal
APLS DEADLINE TODAY: ROSEN, A LEADING NATIONAL FIRM, Encourages Apellis Pharmaceuticals, Inc. Investors to Secure Counsel Before Important October 2 Deadline in Securities Class Action - APLS
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
Exposures Financial Legal
NASDAQ:APLS Shareholder Alert: Deadline on October 2, 2023 Coming Up in Lawsuit Against Apellis Pharmaceuticals, Inc.
San Diego, CA -- (SBWIRE) -- 10/02/2023 -- A deadline is coming up on October 2, 2023 in the lawsuit filed for certain investors of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS). 
Via SBWire
Topics Lawsuit
Exposures Financial Legal
Apellis Announces U.S. FDA Approval of the EMPAVELI® Injector, a Device to Streamline Self-Administration
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
APLS DEADLINE: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Apellis Pharmaceuticals, Inc. Investors in Excess of $100K to Secure Counsel Before Important October 2 Deadline in Securities Class Action - APLS
WHY: NEW YORK, NY - (NewMediaWire) - September 29, 2023 - Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) between... 
Via TheNewswire.com
Topics Lawsuit
Exposures Financial Legal
APELLIS 72 HOUR DEADLINE ALERT: Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors With Losses in Excess of $100,000 of Deadline in Class Action Lawsuit Against Apellis Pharmaceuticals, Inc. - APLS
From Kahn Swick & Foti, LLC
Via Business Wire
APELLIS DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Apellis Pharmaceuticals, Inc. and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire, P.C.
Via Business Wire
APLS DEADLINE: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Apellis Pharmaceuticals, Inc. Investors in Excess of $100K to Secure Counsel Before Important October 2 Deadline in Securities Class Action - APLS
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
Exposures Financial Legal
The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Apellis Pharmaceuticals, Inc. (APLS)
From The Law Offices of Frank R. Cruz
Via Business Wire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against RTX, Eos, and Apellis and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9
...
17 18 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Use the myMotherLode.com Keyword Search to go straight to a specific page

Popular Pages

  • Local News
  • US News
  • Weather
  • State News
  • Events
  • Traffic
  • Sports
  • Dining Guide
  • Real Estate
  • Classifieds
  • Financial News
  • Fire Info
Terms of Service Privacy Policy
© Copyright 2000-2019 Clarke Broadcasting Corporation. All rights reserved.
Feedback